Taiwan · Delayed Price · Currency is TWD Syngen Biotech Statistics
Total Valuation
Syngen Biotech has a market cap or net worth of TWD 3.13 billion. The enterprise value is 3.08 billion.
| Market Cap | 3.13B |
| Enterprise Value | 3.08B |
Important Dates
The next estimated earnings date is Wednesday, March 4, 2026.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | Jun 26, 2025 |
Share Statistics
Syngen Biotech has 27.10 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 27.10M |
| Shares Outstanding | 27.10M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 7.00% |
| Owned by Institutions (%) | 3.25% |
| Float | 11.85M |
Valuation Ratios
The trailing PE ratio is 11.54.
| PE Ratio | 11.54 |
| Forward PE | n/a |
| PS Ratio | 1.47 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | 12.23 |
| P/OCF Ratio | 9.80 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.75, with an EV/FCF ratio of 12.03.
| EV / Earnings | 11.34 |
| EV / Sales | 1.44 |
| EV / EBITDA | 6.75 |
| EV / EBIT | 9.19 |
| EV / FCF | 12.03 |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.20 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 0.88 |
| Interest Coverage | 57.84 |
Financial Efficiency
Return on equity (ROE) is 11.78% and return on invested capital (ROIC) is 11.39%.
| Return on Equity (ROE) | 11.78% |
| Return on Assets (ROA) | 6.66% |
| Return on Invested Capital (ROIC) | 11.39% |
| Return on Capital Employed (ROCE) | 12.93% |
| Weighted Average Cost of Capital (WACC) | 5.20% |
| Revenue Per Employee | 8.65M |
| Profits Per Employee | 1.10M |
| Employee Count | 247 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 4.00 |
Taxes
In the past 12 months, Syngen Biotech has paid 63.25 million in taxes.
| Income Tax | 63.25M |
| Effective Tax Rate | 18.89% |
Stock Price Statistics
The stock price has decreased by -10.81% in the last 52 weeks. The beta is 0.21, so Syngen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -10.81% |
| 50-Day Moving Average | 122.61 |
| 200-Day Moving Average | 126.13 |
| Relative Strength Index (RSI) | 33.94 |
| Average Volume (20 Days) | 88,505 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Syngen Biotech had revenue of TWD 2.14 billion and earned 271.59 million in profits. Earnings per share was 10.01.
| Revenue | 2.14B |
| Gross Profit | 723.59M |
| Operating Income | 326.98M |
| Pretax Income | 334.84M |
| Net Income | 271.59M |
| EBITDA | 448.31M |
| EBIT | 326.98M |
| Earnings Per Share (EPS) | 10.01 |
Balance Sheet
The company has 275.47 million in cash and 225.19 million in debt, with a net cash position of 50.27 million or 1.86 per share.
| Cash & Cash Equivalents | 275.47M |
| Total Debt | 225.19M |
| Net Cash | 50.27M |
| Net Cash Per Share | 1.86 |
| Equity (Book Value) | 2.37B |
| Book Value Per Share | 87.52 |
| Working Capital | 621.61M |
Cash Flow
In the last 12 months, operating cash flow was 319.48 million and capital expenditures -63.56 million, giving a free cash flow of 255.92 million.
| Operating Cash Flow | 319.48M |
| Capital Expenditures | -63.56M |
| Free Cash Flow | 255.92M |
| FCF Per Share | 9.44 |
Margins
Gross margin is 33.87%, with operating and profit margins of 15.30% and 12.71%.
| Gross Margin | 33.87% |
| Operating Margin | 15.30% |
| Pretax Margin | 15.67% |
| Profit Margin | 12.71% |
| EBITDA Margin | 20.98% |
| EBIT Margin | 15.30% |
| FCF Margin | 11.98% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 4.20%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 4.20% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 49.89% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 4.19% |
| Earnings Yield | 8.68% |
| FCF Yield | 8.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Jul 9, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Syngen Biotech has an Altman Z-Score of 5.02 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.02 |
| Piotroski F-Score | 6 |